Hepatitis B vaccination: Are escape mutant viruses a matter of concern?

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 1, 2015, Pages 53-57

  Romanò, Luisa ^a   Paladini, Sara ^a   Galli, Cristina ^a   Raimondo, Giovanni ^b   Pollicino, Teresa ^b   Zanetti, Alessandro R ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Drug resistant mutants; HBV; HBV escape mutants; Hepatitis B; Vaccination

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; MUTANT PROTEIN; NEUTRALIZING ANTIBODY;

BLOOD; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE EVASION; IMMUNOLOGY; ITALY; MISSENSE MUTATION; PROCEDURES; UTILIZATION; VACCINATION;

ANTIBODIES, NEUTRALIZING; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNE EVASION; ITALY; MUTANT PROTEINS; MUTATION, MISSENSE; VACCINATION;

EID: 84949117805     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.34306     Document Type: Conference Paper

References (41)

1. World Health Organization. Hepatitis B. 2008. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/ (last access 18 june 2014).
2. World Health Organization, Regional Office for Europe. Hepatitis B and C infect one in fifty adults in European Region. Available at: http://www.euro.who.int/en/health-topics/communicable-diseases/hepatitis/news/news/2013/06/hepatitis-b-and-c-infect-one-in-fifty-adults-in-european-region# (last access 18 june 2014).
3. World Health Organization. WHO expanded programme on immunisation. Global Advisory Group. Wkly Epidemiol Rec 1992; 3:11-6
4. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26:6266-73; PMID:18848855; http://dx.doi.org/10.1016/j.vaccine.2008.09.056
5. Ganem D, Schneider RJ. Hepadnaviridae: the viruses and their replication. In: Knipe DM, et al., eds. Fields Virology, 4th ed. Philadelphia, Lippincott Williams & Wilkins, 2001:2923-69
6. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64:51-68; PMID:10704474; http://dx.doi.org/10.1128/MMBR.64.1.51-68.2000
7. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359:1486-500; PMID:18832247; http://dx.doi.org/10.1056/NEJMra0801644
8. Rossner MT. Review: hepatitis B virus X-gene product: a promiscuous transcriptional activator. J Med Virol 1992; 36:101-17; PMID:1583465; http://dx.doi.org/10.1002/jmv.1890360207
9. Prince AM, Ikram H, Hopp TP. Hepatitis B virus vaccine: identification of HBsAg/a and HBsAg/d but not HBsAg/y subtype antigenic determinants on a synthetic immunogenic peptide. Proc Natl Acad Sci U S A 1982; 79:579-82; PMID:6176997; http://dx.doi.org/10.1073/pnas.79.2.579
10. Norder H, Couroucé AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004; 47:289-309; PMID:15564741; http://dx.doi.org/10.1159/000080872
11. Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T, Häussinger D. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54:1009-13; PMID:15951551; http://dx.doi.org/10.1136/gut.2004.060327
12. Schaefer S. Hepatitis B virus: significance of genotypes. J Viral Hepat 2005; 12:111-24; PMID:15720525; http://dx.doi.org/10.1111/j.1365-2893.2005.00584.x
13. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373:582-92; PMID:19217993; http://dx.doi.org/10.1016/S0140-6736(09)60207-5
14. Pujol FH, Navas MC, Hainaut P, Chemin I. Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. Cancer Lett 2009; 286:80-8; PMID:19683385; http://dx.doi.org/10.1016/j.canlet.2009.07.013
15. Guirgis BS, Abbas RO, Azzazy HM. Hepatitis B virus genotyping: current methods and clinical implications. Int J Infect Dis 2010; 14:e941-53; PMID:20674432; http://dx.doi.org/10.1016/j.ijid.2010.03.020
16. Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 1995; 345:1406-7; PMID:7539089; http://dx.doi.org/10.1016/S0140-6736(95)92599-6
17. Mimms L. Hepatitis B virus escape mutants: "pushing the envelope" of chronic hepatitis B virus infection. Hepatology 1995; 21:884-7; PMID:7875688
18. Jongerius JM, Wester M, Cuypers HT, van Oostendorp WR, Lelie PN, van der Poel CL, van Leeuwen EF. New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion 1998; 38:56-9; PMID:9482395; http://dx.doi.org/10.1046/j.1537-2995.1998.38198141499.x
19. Coleman PF, Chen YC, Mushahwar IK. Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol 1999; 59:19-24; PMID:10440803; http://dx.doi.org/10.1002/(SICI)1096-9071(199909)59:1〈19::AID-JMV4〉3.0.CO;2-B
20. Zanetti AR, Tanzi E, Manzillo G, Maio G, Sbreglia C, Caporaso N, Thomas H, Zuckerman AJ. Hepatitis B variant in Europe. Lancet 1988; 2:1132-3; PMID:2460710; http://dx.doi.org/10.1016/S0140-6736(88)90541-7
21. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC. Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336:325-9; PMID:1697396; http://dx.doi.org/10.1016/0140-6736(90)91874-A
22. Ogata N, Zanetti AR, Yu M, Miller RH, Purcell RH. Infectivity and pathogenicity in chimpanzees of a surface gene mutant of hepatitis B virus that emerged in a vaccinated infant. J Infect Dis 1997; 175:511-23; PMID:9041321; http://dx.doi.org/10.1093/infdis/175.3.511
23. Hsu HY, Chang MH, Ni YH, Lin HH, Wang SM, Chen DS. Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis. Hepatology 1997; 26:786-91; PMID:9303514; http://dx.doi.org/10.1002/hep.510260336
24. Carman W, Thomas HC, Zuckerman AJ, et al. Molecular variants of hepatitis B virus. In: Zuckerman A, Thomas HC ed. Viral Hepatitis. 2nd ed. London, Churchill Livingstone, 1998: 141-72.
25. Zuckerman AJ. Effect of hepatitis B virus mutants on efficacy of vaccination. Lancet 2000; 355:1382-4; PMID:10791517; http://dx.doi.org/10.1016/S0140-6736(00)02132-2
26. Hsu HY, Chang MH, Ni YH, Chen HL. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 2004; 53:1499-503; PMID:15361503; http://dx.doi.org/10.1136/gut.2003.034223
27. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Büschenfelde KH, Neuhaus P, Gerken G. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27:254-63; PMID:9425945; http://dx.doi.org/10.1002/hep.510270138
28. Nainan OV, Khristova ML, Byun K, Xia G, Taylor PE, Stevens CE, Margolis HS. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol 2002; 68:319-27; PMID:12226817; http://dx.doi.org/10.1002/jmv.10206
29. Hsu HY, Chang MH, Ni YH, Chiang CL, Chen HL, Wu JF, Chen PJ. No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization. J Infect Dis 2010; 201:1192-200; PMID:20210630; http://dx.doi.org/10.1086/651378
30. Bian T, Yan H, Shen L, Wang F, Zhang S, Cao Y, Zhang S, Zhang Y, Bi S. Change in hepatitis B virus large surface antigen variant prevalence 13 years after implementation of a universal vaccination program in China. J Virol 2013; 87:12196-206; PMID:24006443; http://dx.doi.org/10.1128/JVI.02127-13
31. Bian T, Yan H, Shen L, Wang F, Zhang S, Cao Y, et al. Universal hepatitis B vaccination in China boosts breakthrough mutant viruses. Microbe 2013; 8:393-4
32. Jilg W, Norder H, Kane M, Van Damme P, Vorsters A. Viral Hepatitis Prevention Board. Reduced prevalence of HBsAg variants following a successful immunization program in China. J Virol 2014; 88:4605-6; PMID:24672049; http://dx.doi.org/10.1128/JVI.03654-13
33. Locarnini S, Shouval D. Commonly found variations/mutations in the HBsAg of hepatitis B virus in the context of effective immunization programs: questionable clinical and public health significance. J Virol 2014; 88:6532; PMID:24803487; http://dx.doi.org/10.1128/JVI.00234-14
34. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167-85; PMID:22436845
35. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137:1593-608, e1-2; PMID:19737565; http://dx.doi.org/10.1053/j.gastro.2009.08.063
36. Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis 2012; 12:341-53; PMID:22326017; http://dx.doi.org/10.1016/S1473-3099(11)70314-0
37. Pollicino T, Cacciola I, Saffioti F, Raimondo G. Hepatitis B Virus PreS/S Gene Variants: Pathobiology and Clinical Implications. J Hepatol 2014; 61:408-17; PMID:24801416; http://dx.doi.org/10.1016/j.jhep.2014.04.041
38. Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol 2012; 57:730-5; PMID:22668640; http://dx.doi.org/10.1016/j.jhep.2012.05.021
39. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, et al.; Taiwan Hepatoma Study Group. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101:1348-55; PMID:19759364; http://dx.doi.org/10.1093/jnci/djp288
40. SEIEVA. Sistema Epidemiolgico Integrato dell'Epatite Virale Acuta. Istituto Superiore di Sanità, Roma. Available at http://www.iss.it/binary/seie/cont/Tassi-EpatiteB-2012.pdf (last access: 18 june 2014).
41. Da Villa G, Romanò L, Sepe A, Iorio R, Paribello N, Zappa A, Zanetti AR. Impact of hepatitis B vaccination in a highly endemic area of south Italy and longterm duration of anti-HBs antibody in two cohorts of vaccinated individuals. Vaccine 2007; 25:3133-6; PMID:17280750; http://dx.doi.org/10.1016/j.vaccine.2007.01.044